“…ETF was administered via a gastrostomy tube in 15 studies; in one of these studies, ETF was delivered via a nasogastric tube in some patients [ 12 ]. In these 15 studies, 33.3–100% of patients had stroke [ 11 , 12 , 13 , 17 , 24 , 25 , 26 , 27 , 28 ], 20.0–60.0% had dementia [ 11 , 12 , 17 , 25 , 26 , 27 ], 46.1% had respiratory disorders [ 26 ], 18.5% had dysphagia [ 17 ], 15.3% had neurodegenerative disorders [ 26 ], 13.7% had malignancy [ 26 ], 6.7% had neuromuscular disorders [ 12 ], 7.4% had hypoxic encephalopathy [ 27 ], 7.4% had esophageal cancer [ 27 ], 3.7% had gastric cancer [ 27 ], 3.7% had brain tumor surgery [ 27 ], 3.7% had cerebral contusion [ 27 ], and 3.7% had disuse syndrome [ 27 ]. Comorbidities were as follows: 12.1–25.6% had diabetes mellitus [ 13 , 26 ], 3.4–86.4% had hiatal hernia [ 12 , 13 , 26 ], 40% had reflux esophagitis [ 12 ], 10.6% had pneumoperitoneum [ 13 ], 4.5% had gastric bleeding [ 13 ], and 2.6% had partial gastric resection [ 26 ].…”